Lung NeoplasmNCT00469066
Cone Beam CT Scanning in Lung and Bladder Cancer.
An observational study of Lung Neoplasm and Small Cell Carcinoma, run by AHS Cancer Control Alberta at 1 site in Canada.
Trial summary
To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Neoplasm, Small Cell Carcinoma, Bladder Carcinoma
- How many people
- 22 participants
- Where
- 1 siteCanada
- Study dates
- May 2007to Apr 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: primary care clniic
Who may be able to join
- Patient has biopsy proven limited stage SCLC
- receiving radical concurrent chemoradiotherapy
- no prior chest RT
- no prior surgical resection of lung tumor
- no prior chemotherapy
- patients' lung tumors should be centrally-located to minimize the effect of respiratory motion
Show all 10Show fewer
- patient has biopsy proven TCC bladder
- receiving radical concurrent chemoradiotherapy or RT alone
- no prior chemotherapy
- patient signs study-specific consent form
Who cannot join
- mixed small cell and non small cell histology
- patient not being treated with concurrent chemoradiotherapy
- chemoradiotherapy given sequentially
- previous chest RT
- previous chemotherapy
- prior surgical resection of lung mass
- patient ineligible for pelvic RT
- patient does not sign study consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging
To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.
- Conditions
- Lung Neoplasm, Small Cell Carcinoma, Bladder Carcinoma
- Keywords
- small cell lung cancer, bladder cancer, conformal radiotherapy
- Medical subject headings
- Lung Neoplasms, Carcinoma, Small Cell, Urinary Bladder Neoplasms, Small Cell Lung Carcinoma
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2007 (estimated)
- Study startMay 2007
- Primary completionAug 2009
- Study completionApr 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- AHS Cancer Control Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Cross Cancer Institute
- Responsible party
- Sponsor
- Investigators
- Don Yee, MD, Principal investigator, AHS Cancer Control Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00469066
- Sponsor's protocol ID
- LU-11-0073
- Status last verified
- Dec 2011
- First submitted
- 2 May 2007
- Last updated
- 24 Feb 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging
- ClinicalTrials.gov ID
- NCT00469066
- Acronym / sponsor ID
- LU-11-0073
- Conditions
- Lung Neoplasm, Small Cell Carcinoma, Bladder Carcinoma
- Keywords
- small cell lung cancer, bladder cancer, conformal radiotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- AHS Cancer Control AlbertaUniversity, hospital or other
- Collaborators
- Cross Cancer Institute
- Study start
- May 2007
- Primary completion
- Aug 2009 (actual)
- Study completion
- Apr 2010 (actual)
- First posted
- 4 May 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- primary care clniic
Key inclusion criteria (10 listed)
- Patient has biopsy proven limited stage SCLC
- receiving radical concurrent chemoradiotherapy
- no prior chest RT
- no prior surgical resection of lung tumor
- no prior chemotherapy
Key exclusion criteria (8 listed)
- mixed small cell and non small cell histology
- patient not being treated with concurrent chemoradiotherapy
- chemoradiotherapy given sequentially
- previous chest RT
- previous chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2016.
Related trials for Lung Neoplasm
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Don Yee, MD principal investigator
AHS Cancer Control Alberta
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Neoplasm and Small Cell Carcinoma, run by AHS Cancer Control Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2016.